The antiviral drug remdesivir (Veklury) was associated with faster clinical improvement in hospitalized COVID-19 patients in a multicenter comparative-effectiveness study published yesterday in JAMA Network Open.The retrospective study, conducted by Johns Hopkins University researchers, involved 2,299 COVID-19 patients receiving care in a 5-hospital health system in the Baltimore and Washington, DC, area from Mar 4 to Aug 29, 2020.
About 15% percent received remdesivir (342) as part of their treatment, of which 285 were matched with controls for primary statistical analysis.Clinical improvement was defined as release from the hospital without worsening of World Health Administration (WHO) severity score during hospitalization or within 28